AdvisorShares Psychedelics ETF(PSIL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$16.68
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PSIL

11/20/2026: PSIL (1-star) is currently NOT-A-BUY. Pass it for now.

The AdvisorShares Psychedelics ETF (PSIL) provides actively managed exposure to global companies leading the legal development of psychedelic medicines and therapeutics for mental health. Its primary strengths lie in its dedicated thematic focus, active management flexibility, and daily transparency, offering a turnkey vehicle for a hard-to-access sector. It serves best as a satellite growth allocation for high-risk portfolios seeking exposure to medical innovation. Key risks include high volatility, micro-cap concentration, clinical trial uncertainties, and a relatively high 1.00% expense ratio. Investors should closely monitor regulatory progress, clinical milestones, and broader sentiment toward speculative biotech assets.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitSuits investors seeking high-growth potential driven by disruptive medical science and emerging pharmaceutical markets.
Momentum investorStrong fit while signal remains positiveCan capture sharp upward momentum phases during positive clinical trial or regulatory headline cycles.
Value investorWeak fitThe fund holds pre-revenue or early-stage clinical companies that lack traditional value metrics.
Dividend/Income investorWeak fitThe underlying holdings do not pay regular dividends, focusing instead on clinical research and corporate expansion.
Low-risk investorWeak fitHigh volatility, micro-cap exposure, and binary clinical trial outcomes expose investors to severe downside risk.

Investor Profile

Ideal Investor Profile

Risk-tolerant growth investors seeking speculative thematic exposure to the future of mental health therapeutics and psychedelic drug development.

Suitability

Best suited for tactical growth allocations rather than core long-term portfolio holdings or passive index strategies.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighThe fund's focus on micro- and small-cap clinical biotech stocks drives sharp price swings.
Market riskHighAdverse macro conditions or shifts in risk-on sentiment can heavily impact speculative equities.
ConcentrationHighPortfolios are tightly concentrated within a single emerging industry and a limited number of holdings.
Tracking/expenseMedium / highAn expense ratio of 1.00% creates a notable hurdle for long-term compounding performance.
LiquidityHighLower AUM and thinly traded underlying components can result in wider trading spreads.
Business/sector qualityHighMany portfolio companies are pre-revenue entities reliant on successful drug approvals and external financing.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

PSIL exhibits very high historical volatility driven by speculative small-cap biotechnology assets and shifting regulatory frameworks.

Market Risk

Underlying assets face high binary clinical trial risk, cash-burn pressures, and sensitivity to broader macroeconomic liquidity cycles.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
IndustryBiotechnology & Pharmaceutical Therapeutics (e.g., Compass Pathways, Atai Life Sciences)85Provides targeted equity exposure to clinical-stage companies developing psychedelic-based treatments for mental health conditions.
SectorGlobal Healthcare and Life Sciences15Adds foundational life sciences exposure and broader medical sector diversification to cushion thematic volatility.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type ETF
Historic Profit 21.95%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
ETF Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.